| Neeraj Chaudhary, MD | |
|
1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 | |
| (734) 936-4000 | |
| Not Available |
| Full Name | Neeraj Chaudhary |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 28 Years |
| Location | 1500 E Medical Center Dr, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265684450 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085N0700X | Radiology - Neuroradiology | 4301092784 (Michigan) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 4301092784 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Michigan Health System | Ann arbor, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of Michigan | 3779496856 | 2953 |
News Archive
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
BioTime, Inc. announced today the publication of a scientific paper demonstrating the effectiveness of HyStem-C in the transplantation of heart muscle-derived cells in an animal model of heart disease.
The State Government of Victoria, Australia announced that Melbourne scientists at Monash University have developed a unique technology that can grow large numbers of blood cells from human embryonic stem cells.
Marta Artal Sanz, Thomas Brox, Winfried Römer, and Oliver Schilling from the University of Freiburg have been selected for one of the most prestigious European grants for young researchers: The European Research Council (ERC) has awarded them a total of 5.8 million euros in ERC Starting Grants for new projects.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 5 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868353 PECOS PAC ID: 3779496856 Enrollment ID: O20031106000325 |
News Archive
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
BioTime, Inc. announced today the publication of a scientific paper demonstrating the effectiveness of HyStem-C in the transplantation of heart muscle-derived cells in an animal model of heart disease.
The State Government of Victoria, Australia announced that Melbourne scientists at Monash University have developed a unique technology that can grow large numbers of blood cells from human embryonic stem cells.
Marta Artal Sanz, Thomas Brox, Winfried Römer, and Oliver Schilling from the University of Freiburg have been selected for one of the most prestigious European grants for young researchers: The European Research Council (ERC) has awarded them a total of 5.8 million euros in ERC Starting Grants for new projects.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 5 days ago
| Entity Name | Munson Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083761860 PECOS PAC ID: 3072426287 Enrollment ID: O20040108000904 |
News Archive
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
BioTime, Inc. announced today the publication of a scientific paper demonstrating the effectiveness of HyStem-C in the transplantation of heart muscle-derived cells in an animal model of heart disease.
The State Government of Victoria, Australia announced that Melbourne scientists at Monash University have developed a unique technology that can grow large numbers of blood cells from human embryonic stem cells.
Marta Artal Sanz, Thomas Brox, Winfried Römer, and Oliver Schilling from the University of Freiburg have been selected for one of the most prestigious European grants for young researchers: The European Research Council (ERC) has awarded them a total of 5.8 million euros in ERC Starting Grants for new projects.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 5 days ago
| Entity Name | Metropolitan Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811937519 PECOS PAC ID: 5597651836 Enrollment ID: O20040507000012 |
News Archive
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
BioTime, Inc. announced today the publication of a scientific paper demonstrating the effectiveness of HyStem-C in the transplantation of heart muscle-derived cells in an animal model of heart disease.
The State Government of Victoria, Australia announced that Melbourne scientists at Monash University have developed a unique technology that can grow large numbers of blood cells from human embryonic stem cells.
Marta Artal Sanz, Thomas Brox, Winfried Römer, and Oliver Schilling from the University of Freiburg have been selected for one of the most prestigious European grants for young researchers: The European Research Council (ERC) has awarded them a total of 5.8 million euros in ERC Starting Grants for new projects.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Neeraj Chaudhary, MD 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | Neeraj Chaudhary, MD 1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 Ph: (734) 936-4000 |
News Archive
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
BioTime, Inc. announced today the publication of a scientific paper demonstrating the effectiveness of HyStem-C in the transplantation of heart muscle-derived cells in an animal model of heart disease.
The State Government of Victoria, Australia announced that Melbourne scientists at Monash University have developed a unique technology that can grow large numbers of blood cells from human embryonic stem cells.
Marta Artal Sanz, Thomas Brox, Winfried Römer, and Oliver Schilling from the University of Freiburg have been selected for one of the most prestigious European grants for young researchers: The European Research Council (ERC) has awarded them a total of 5.8 million euros in ERC Starting Grants for new projects.
Oncotarget recently published "Simvastatin is a potential candidate drug in ovarian clear cell carcinomas" which reported that based on previous studies, the authors assessed the anti-proliferative effect of simvastatin, a Rho GTPase interfering drug, in three OCCC cell lines: JHOC-5, OVMANA and TOV-21G, and one high-grade serous ovarian cancer cell line, Caov3. The authors used the Rho GTPase interfering drug CID-1067700 as a control.
› Verified 5 days ago
Chiemezie Chianotu Amadi, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Patrick Charles Albus, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Michael James Todd, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Perry G Pernicano, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr, B1 Floor University Hospital Recp C, Ann Arbor, MI 48109 Phone: 734-936-4566 | |
Ellen G Hoeffner, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr, B1 Floor University Hospital Recp C, Ann Arbor, MI 48109 Phone: 734-936-4566 | |
Dr. Christopher Robert Nall, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Stephen Michael Ascherl, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 2375 Newport Rd, Ann Arbor, MI 48103 Phone: 734-327-0649 Fax: 734-327-0649 |